Christopher Proctor
Orthopaedic Surgery · Santa Barbara, CANPI 1033291786
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $593,378 of the $672,630 with a category attached, or 88.2%. Anika Therapeutics, Inc. accounts for 99.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $593,378 and has fallen 100.0% since, to $86 in 2025. Among orthopaedic surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 17 payments — averaging $39,566 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Anika Therapeutics, Inc.$671K
- Lazurite Inc.$1K
- Vertex$86
- Boston Scientific$81
- Smith+Nephew$42
- Bioventus LLC$31
- plus $36 from 2 others
Across 7 payments — averaging $63,817 each. An ownership or investment interest held by the physician or an immediate family member.
- Lazurite Inc.$447K
- Parcus Medical, LLC$0
What the payments were for
- Travel & lodging$1,1100%
- Food & beverage$4560%
- Ownership interest$593,37888%
- Other$77,68512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Anika Therapeutics, Inc. | 4 | $671,063 |
| Lazurite Inc. | 2 | $1,291 |
| Vertex | 3 | $86 |
| Boston Scientific | 3 | $81 |
| Smith+Nephew | 2 | $42 |
| Bioventus LLC | 1 | $31 |
| Johnson & Johnson | 1 | $22 |
| DJO, LLC | 1 | $15 |
How this compares
$672,630 in reported general payments places this provider in the 95th percentile of 1,808 orthopaedic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nabumetone | 11 | $115 |
| Meloxicam | 37 | $113 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Santa Barbara
- Bradford HackArcadia$18.3M
- Robert GorabOrange$13.6M
- Kelly VinceLos Angeles$9.6M
- Stephen HowellSacramento$9.4M
- Thomas CoonRed Bluff$9.2M
- Nirav AminPlacentia$5.6M
- Tom NorrisSan Francisco$5.3M
- Jay LiebermanLos Angeles$4.8M
- Peter NewtonSan Diego$4.2M
- Sigurd BervenSan Francisco$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.